Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Ernexa Therapeutics reported favorable repeat-dose tox, tumorigenicity and biodistribution results for ERNA-101 and said GMP manufacturing is underway, with an IND submission planned for Q4 2026 for platinum-resistant ovarian cancer.Material DetailsContext by AI AnalystThis is an early-stage de-ris…
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine releaseNo teratoma formation observed in ERNA-101-treated animals throu…
The company said ERNA-101 showed safety results across three IND-enabling studies and reiterated plans for a Q4 2026 IND filing.